ProteoGenix launches new XtenCHOTM Transient CHO Expression System to improve biologics development

ProteoGenix, a contract research organization specialized in biologics discovery and bioproduction, announces the launch of its XtenCHO^TM Transient Expression System. Due to its enhanced plasmid stability and optimized metabolism, the new proprietary mammalian cell-based expression host achieves up to ten times higher yields with less hands-on time compared to existing solutions. The new CHO host aims to simplify recombinant protein production and accelerate early phase drug screening.

XtenCHO^TM was developed by ProteoGenix from the parental cell line CHO-K1 by engineering its genome to exhibit properties that ultimately maximize protein production yields. Compared to other commercially available CHO systems, the new cell line has enhanced robustness, recovering quickly after thawing and performing well even in suboptimal conditions.

Its ultra-high yields result from the concerted effect of using an optimized animal component-free growth medium, one-step highly efficient transfection reagent and ultra-high expression vector. These components work together to reduce premature plasmid loss and create a three to ten-fold increase in transient gene expression (TGE) yields in comparison to  market-leading CHO systems.

The new host has been used and optimized by ProteoGenix’s experts for the past 5 years to produce over 3500 recombinant proteins. These have included antibodies from multiple species, isotopes and formats, such as bispecific antibodies, ADCs and nanobodies. In addition, a large number of non-antibody proteins have been produced, including highly functional enzymes, membrane-bound receptors, cytokines, interleukins and transcription factors.

As part of its mission to support research labs around the world, ProteoGenix has launched its XtenCHO^TM Transient Expression System Kit for widespread use within the life science research community. This follows extensive testing and optimisation by the ProteoGenix team. With the ability to perform superior protein folding and human-like post-translational modifications, XtenCHO^TM has proven to be ideal for the small and medium-scale production of monoclonal antibodies.

The new XtenCHO^TM system produces monoclonal antibodies that are indistinguishable from biopharmaceutical-grade biologics produced in stable systems. This eases process scalability and reduces the risks when transitioning from the bench to the clinic.”

Dr. Raphaël Hopfner, CSO and Co-Founder, ProteoGenix.

We wanted to create a product that would not only speed up the process of early drug development, but also to make it safer, more flexible, accessible, easier to integrate into existing biologics discovery workflows and cost-effective reagents to achieve high yields.”

Philippe Funfrock, CEO and Co-Founder, ProteoGenix.

XtenCHO^TM Transient Expression System is for Research Use Only.